UA43391C2 - Спосіб інгібування міжклітинного зчеплення і спосіб інгібування запального процесу та порушеного процесу нормальної коагуляції у пацієнтів з розладами васкулярного ендотелію - Google Patents

Спосіб інгібування міжклітинного зчеплення і спосіб інгібування запального процесу та порушеного процесу нормальної коагуляції у пацієнтів з розладами васкулярного ендотелію

Info

Publication number
UA43391C2
UA43391C2 UA97084166A UA97084166A UA43391C2 UA 43391 C2 UA43391 C2 UA 43391C2 UA 97084166 A UA97084166 A UA 97084166A UA 97084166 A UA97084166 A UA 97084166A UA 43391 C2 UA43391 C2 UA 43391C2
Authority
UA
Ukraine
Prior art keywords
inhibition
disorders
patients
disrupted
vascular endothelium
Prior art date
Application number
UA97084166A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Брайан Уільям ГРІННЕЛЛ
Брайан Уильям Гриннелл
Original Assignee
Елі Ліллі Енд Компані
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Елі Ліллі Енд Компані, Эли Лилли Энд Компани filed Critical Елі Ліллі Енд Компані
Publication of UA43391C2 publication Critical patent/UA43391C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
UA97084166A 1995-02-09 1996-02-09 Спосіб інгібування міжклітинного зчеплення і спосіб інгібування запального процесу та порушеного процесу нормальної коагуляції у пацієнтів з розладами васкулярного ендотелію UA43391C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/385,934 US5484808A (en) 1995-02-09 1995-02-09 Methods of inhibiting cell-cell adhesion
PCT/US1996/002657 WO1996024384A1 (en) 1995-02-09 1996-02-09 Methods of inhibiting cell-cell adhesion

Publications (1)

Publication Number Publication Date
UA43391C2 true UA43391C2 (uk) 2001-12-17

Family

ID=23523494

Family Applications (1)

Application Number Title Priority Date Filing Date
UA97084166A UA43391C2 (uk) 1995-02-09 1996-02-09 Спосіб інгібування міжклітинного зчеплення і спосіб інгібування запального процесу та порушеного процесу нормальної коагуляції у пацієнтів з розладами васкулярного ендотелію

Country Status (17)

Country Link
US (2) US5484808A (ja)
EP (1) EP0726071A2 (ja)
JP (1) JPH10513475A (ja)
KR (1) KR19980702079A (ja)
CN (1) CN1072931C (ja)
AU (1) AU693021B2 (ja)
CA (1) CA2212339A1 (ja)
CZ (1) CZ286448B6 (ja)
HU (1) HUP9801323A3 (ja)
IL (1) IL117079A (ja)
MY (1) MY132251A (ja)
NO (1) NO973635L (ja)
NZ (1) NZ305072A (ja)
RU (1) RU2179021C2 (ja)
UA (1) UA43391C2 (ja)
WO (1) WO1996024384A1 (ja)
ZA (1) ZA961076B (ja)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) * 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5747509A (en) * 1996-06-03 1998-05-05 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
US5773432A (en) * 1996-10-30 1998-06-30 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
WO1998046588A2 (en) 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6008232A (en) * 1997-08-20 1999-12-28 Eli Lilly And Company Methods for preventing headaches
WO1999051587A1 (fr) * 1998-04-01 1999-10-14 Ono Pharmaceutical Co., Ltd. Derives de thiophene condenses et medicaments contenant ceux-ci comme principe actif
ATE301129T1 (de) 1999-05-04 2005-08-15 Strakan Int Ltd Androgen glykoside und die androgenische aktivität davon
US6359015B1 (en) 2000-02-28 2002-03-19 The United States Of America As Represented By The Department Of Veterans Affairs Method for antagonizing inhibition effects of alcohol on cell adhesion
US20030027135A1 (en) * 2001-03-02 2003-02-06 Ecker David J. Method for rapid detection and identification of bioagents
US20040121313A1 (en) 2002-12-06 2004-06-24 Ecker David J. Methods for rapid detection and identification of bioagents in organs for transplantation
US7666588B2 (en) 2001-03-02 2010-02-23 Ibis Biosciences, Inc. Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
JP3887588B2 (ja) * 2002-08-30 2007-02-28 株式会社リガク Ｘ線回折による応力測定法
US6977272B2 (en) * 2002-10-16 2005-12-20 President And Fellows Of Harvard College Method for antagonizing inhibition effects of alcohol on cell adhesion
CA2508726A1 (en) * 2002-12-06 2004-07-22 Isis Pharmaceuticals, Inc. Methods for rapid identification of pathogens in humans and animals
US7964343B2 (en) * 2003-05-13 2011-06-21 Ibis Biosciences, Inc. Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
US8546082B2 (en) 2003-09-11 2013-10-01 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8097416B2 (en) 2003-09-11 2012-01-17 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US20120122103A1 (en) * 2003-09-11 2012-05-17 Rangarajan Sampath Compositions for use in identification of bacteria
US20050266411A1 (en) * 2004-05-25 2005-12-01 Hofstadler Steven A Methods for rapid forensic analysis of mitochondrial DNA
WO2006135400A2 (en) 2004-08-24 2006-12-21 Isis Pharmaceuticals, Inc. Methods for rapid identification of recombinant organisms
US8026084B2 (en) * 2005-07-21 2011-09-27 Ibis Biosciences, Inc. Methods for rapid identification and quantitation of nucleic acid variants
CN107412248A (zh) 2016-05-24 2017-12-01 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷在治疗血管炎症或改善血管内皮功能中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US5356926A (en) * 1992-02-24 1994-10-18 Warner-Lambert Company 3-alkyloxy-, aryloxy-, or arylalkyloxy-benzo [β]thiophene-2-carboxamides as inhibitors of cell adhesion
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
CN1058390C (zh) * 1993-10-15 2000-11-15 伊莱利利公司 苯并噻吩类化合物的用途
US5457113A (en) * 1993-10-15 1995-10-10 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell proliferation and restinosis
US5574047A (en) * 1993-12-21 1996-11-12 Eli Lilly And Company Methods of inhibiting imperfect tissue repair
US5441965A (en) * 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting thrombin
US5476862A (en) * 1993-12-21 1995-12-19 Eli Lilly And Company Methods of increasing thrombomodulin expression

Also Published As

Publication number Publication date
CN1072931C (zh) 2001-10-17
US5484808A (en) 1996-01-16
EP0726071A2 (en) 1996-08-14
EP0726071A3 (ja) 1996-09-11
MX9706072A (es) 1997-10-31
NZ305072A (en) 2000-07-28
AU693021B2 (en) 1998-06-18
KR19980702079A (ko) 1998-07-15
WO1996024384A1 (en) 1996-08-15
CA2212339A1 (en) 1996-08-15
CZ286448B6 (en) 2000-04-12
RU2179021C2 (ru) 2002-02-10
MY132251A (en) 2007-09-28
HUP9801323A3 (en) 1999-09-28
AU5299696A (en) 1996-08-27
IL117079A (en) 1999-12-31
NO973635L (no) 1997-09-29
NO973635D0 (no) 1997-08-06
CN1173821A (zh) 1998-02-18
IL117079A0 (en) 1996-06-18
CZ248297A3 (cs) 1998-06-17
HUP9801323A2 (hu) 1999-05-28
JPH10513475A (ja) 1998-12-22
ZA961076B (en) 1997-08-11
US5496851A (en) 1996-03-05

Similar Documents

Publication Publication Date Title
UA43391C2 (uk) Спосіб інгібування міжклітинного зчеплення і спосіб інгібування запального процесу та порушеного процесу нормальної коагуляції у пацієнтів з розладами васкулярного ендотелію
AU8155894A (en) Methods of inhibiting thrombin
MY132056A (en) Methods of inhibiting physiological conditions associated with an excess of neuropeptide y.
MX9701329A (es) Metodos para la inhibicion de la replicacion viral.
PT651999E (pt) Metodos de inibicao da fibrose uterina
MX9701360A (es) Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
MY112973A (en) Methods for inhibiting vascular smooth muscle cell migration
UA27910C2 (uk) Засіб для підвищення експресії тромбомодуліну та підвищення активації протеїну с
MX9709466A (es) Medicamento para inhibir el melanoma.
MY113406A (en) Methods of inhibiting physiological conditions associated with an excess of bradykinin
MX9701333A (es) Metodos para inhibir el daño neuronal.
AU8155094A (en) Methods of inhibiting hirsutism and alopecia in women
MX9702148A (es) Metodos para inhibir la mitosis endometrial.
MX9701327A (es) Metodos para inhibir el cancer endometrial.
MX9701331A (es) Metodos para mantener los dientes y los huesos bucales.
MX9701359A (es) Metodos para la inhibicion de la hiperplasia endometrial primaria.
MX9709536A (es) Metodo para reducir el factor de transcripcion bef-1.
MX9701328A (es) Metodos de reduccion de la cicatrizacion en la curacion de heridas.
MX9705215A (es) Uso de 2-fenil-3-aroilbenzotiofenos para inhibir los efectos de la hormona del crecimiento.
MX9709651A (es) Metodos para modulacion del factor de transcripcion nf-kb.
MX9705940A (es) Metodos y composiciones para inhibir los efectos de la interleucina 6.
MX9706520A (es) Metodos para inhibir el cancer de ovario.
MX9705697A (es) Metodos para reducir los niveles de calcio del suero.
MX9705537A (es) Metodos y composiciones para inhibir el efecto de los estrogenos del medio ambiente.